A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2013

Study Completion Date

September 4, 2017

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Entecavir

Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response

Trial Locations (19)

100

Local Institution, Taipei

1200

Local Institution, Brussels

1425

Local Institution, Buenos Aires

10029

Mount Sinai School Of Medicine, New York

19104

Children'S Hospital Of Philadelphia, Philadelphia

21287

Johns Hopkins School Of Medicine, Baltimore

32610

University Of Florida, Gainesville

75390

University Of Texas Southwestern Medical Center, Dallas

90035

Local Institution, Porto Alegre

94143

University of California, San Francisco, San Francisco

06106

Connecticut Children'S Medical Center, Hartford

02115

Boston Childrens Hospital, Boston

02903

Rhode Island Hospital, Providence

05403

Local Institution, Sco Paulo

M5G 1X8

Local Institution, Toronto

135-710

Local Institution, Seoul

138-736

Local Institution, Seoul

SE5 9RS

Local Institution, London

B4 6NH

Local Institution, Birmingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY